DelveInsight’s “Hemophilia- Market Insights, Epidemiology and Market Forecast-2023-7MM†Reports provides an overview of the disease and global market size of the Hemophilia for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Hemophilia from 2013-2023. Hemophilia is the most common inherited bleeding disorder which leads to spontaneous bleeding as the blood does not clot properly. Hemophilia is characterized by the spontaneous bleeding and swollen joints due to bleeding into the joints. Hemophilia can be mild, moderate, or severe, depending on amount of clotting factor present in the blood. According to DelveInsight, the market size for Hemophilia of 7MM is estimated to be USD XX Million by 2023 at a CAGR of 6.35% for the forecast period i.e., 2013-2023. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
• The report will help in developing business strategies by understanding the trends shaping and driving the Hemophilia market.
• Organize sales and marketing efforts by identifying the best opportunities for Hemophilia in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
• To understand the future market competition in the 7MM market of Hemophilia and Insightful review of the key market drivers and barriers.
• To understand the regulatory scenario in major markets.
• The Report also covers the detailed historical and forecasted Hemophilia market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.
List of Tables
Table 1: 7MM Market Size of Hemophilia in USD Million (2013-2023)
Table 2: Prevalent Population of Hemophilia in United States (2013-2023)
Table 3: Sub-Type Specific Prevalent Population of Hemophilia in the United States (2013-2023)
Table 4: Prevalent Population of Hemophilia in the United Kingdom (2013-2023)
Table 5: Sub-Type Specific Prevalence of Hemophilia in United Kingdom (2013-2023)
Table 6: Prevalent Population of Hemophilia in France (2013-2023)
Table 7: Sub-Type Specific Prevalence of Hemophilia in France (2013-2023)
Table 8: Prevalent Population of Hemophilia in Italy (2013-2023)
Table 9: Sub-Type Specific Prevalence of Hemophilia in Italy (2013-2023)
Table 10: Prevalent Population of Hemophilia in Germany (2013-2023)
Table 11: Sub-Type Specific Prevalence of Hemophilia in Germany (2013-2023)
Table 12: Prevalent Population of Hemophilia in Spain (2013-2023)
Table 13: Sub-Type Specific Prevalence of Hemophilia in Spain (2013-2023)
Table 14: Prevalent Population of Hemophilia in Japan (2013-2023)
Table 15: Sub-Type Specific Prevalent Population of Hemophilia in Japan (2013-2023)
Table 16: List of Marketed Drugs
Table 17: List of Pipeline Drugs for Hemophilia
Table 18: LR769, Clinical Trials by Zone, 2017
Table 19: Clinical Trials by Recruitment status, 2017
Table 20: Emicizumab, Clinical Trials by Zone, 2017
Table 21: Clinical Trials by Recruitment status, 2017
Table 22: Damoctocog alfa pegol, Clinical Trials by Zone, 2017
Table 23: Clinical Trials by Recruitment status, 2017
Table 24: Turoctocog alfa pegol, Clinical Trials by Zone, 2017
Table 25: Clinical Trials by Recruitment status, 2017
Table 26: United States Market Size of Hemophilia in USD, Million (2013-2023)
Table 27: United States- Hemophilia Market Distribution by Type (2013-2023)
Table 28: Germany Market Size of Hemophilia in USD, Million (2013-2023)
Table 29: Germany - Hemophilia Market Distribution by Type (2013-2023)
Table 30: France Market Size of Hemophilia in USD, Million (2013-2023)
Table 31: France - Hemophilia Market Distribution by Type (2013-2023)
Table 32: United Kingdom Market Size of Hemophilia in USD, Million (2013-2023)
Table 33: United Kingdom - Hemophilia Market Distribution by Type (2013-2023)
Table 34: Spain Market Size of Hemophilia in USD, Million (2013-2023)
Table 35: Spain - Hemophilia Market Distribution by Type (2013-2023)
Table 36: Italy Market Size of Hemophilia in USD, Million (2013-2023)
Table 37: Italy - Hemophilia Market Distribution by Type (2013-2023)
Table 38: Japan Market Size of Hemophilia in USD, Million (2013-2023)
Table 39: Japan - Hemophilia Market Distribution by Type (2013-2023)
List of Figures
Figure 1:Types of Hemophilia
Figure 2:Risk factors of Hemophilia
Figure 3:Treatment of Hemophilia
Figure 4: Prevalent Population of Hemophilia in the United States (2013-2023)
Figure 5:Sub-Type Specific Prevalent Population Of Hemophilia in the United States (2013-2023)
Figure 6: Prevalent Population of Hemophilia in the United Kingdom (2013-2023)
Figure 7: Sub-Type Specific Prevalence of Hemophilia in the United Kingdom (2013-2023)
Figure 8: Prevalent Population of Hemophilia in France (2013-2023)
Figure 9: Sub-Type Specific Prevalence of Hemophilia in France (2013-2023)
Figure 10: Prevalent Population of Hemophilia in Italy (2013-2023)
Figure 11: Sub-Type Specific Prevalence of Hemophilia in Italy (2013-2023)
Figure 12: Prevalent Population of Hemophilia in Germany (2013-2023)
Figure 13: Sub-Type Specific Prevalence of Hemophilia in Germany (2013-2023)
Figure 14: Prevalent Population of Hemophilia in Spain (2013-2023)
Figure 15: Sub-Type Specific Prevalence of Hemophilia in Spain (2013-2023)
Figure 16: Prevalent Population of Hemophilia in Japan (2013-2023)
Figure 17: Sub-Type Specific Prevalent Population of Hemophilia in Japan (2013-2023)
Figure 18:Treatment algorithm for Hemophilia
Figure 19: LR769, Clinical Trials by Zone (%), 2017
Figure 20: LR769, Clinical Trials by Recruitment status (%), 2017
Figure 21: Emicizumab, Clinical Trials by Zone (%), 2017
Figure 22: Emicizumab, Clinical Trials by Recruitment status (%), 2017
Figure 23: Damoctocog alfa pegol, Clinical Trials by Zone (%), 2017
Figure 24: Damoctocog alfa pegol, Clinical Trials by Recruitment status (%), 2017
Figure 25: Turoctocog alfa pegol, Clinical Trials by Zone (%), 2017
Figure 26: Turoctocog alfa pegol, Clinical Trials by Recruitment status (%), 2017
Figure 27: Region specific market distribution and comparison
Figure 28: Total 7 Major Market Size of Hemophilia in USD, Million (2016)
Figure 29: Total 7 Major Market Size of Hemophilia in USD, Million (2023)
Figure 30: United States Market Size of Hemophilia in USD, Million (2013-2023)
Figure 31: United States Hemophilia Market Distribution by Type (2013-2023)
Figure 32: Germany Market Size of Hemophilia in USD, Million (2013-2023)
Figure 33: Germany Hemophilia Market Distribution by Type (2013-2023)
Figure 34: France Market Size of Hemophilia in USD, Million (2013-2023)
Figure 35: France Hemophilia Market Distribution by Type (2013-2023)
Figure 36: United Kingdom Market Size of Hemophilia in USD, Million (2013-2023)
Figure 37: United Kingdom Hemophilia Market Distribution by Type (2013-2023)
Figure 38: Spain Market Size of Hemophilia in USD, Million (2013-2023)
Figure 39: Spain Hemophilia Market Distribution by Type (2013-2023)
